Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 Journal Article


Authors: Rustin, G. J. S.; Nelstrop, A. E.; McClean, P.; Brady, M. F.; McGuire, W. P.; Hoskins, W. J.; Mitchell, H.; Lambert, H. E.
Article Title: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125
Abstract: Purpose: To produce definitions based on serial CA 125 levels to measure response of ovarian carcinoma in patients receiving first-line chemotherapy. Patients and Methods: Definitions were derived from analysis of 277 patients in North Thames Ovary Trial 3. Patient data were then incorporated into a computer program and tested against 254 patients in North Thames Ovary Trial 4 and 458 patients in Gynecologic Oncology Group (GOG) protocol 97. For optimum detection of response, three response definitions have been combined into a computer program, The precise definitions use mathematic logic and take account of factors such as intervening samples, Response to a specific treatment has occurred if after two samples there has been a 50% decrease, confirmed by a fourth sample (50% response), or a serial decrease over three samples of greater than 75% (75% response), The final sample has to be at least 28 days after the previous sample. Results: Six hundred twenty of 989 patients were considered assessable for response according to CA 125 level. Only two patients (0.3%) had a CA 125 response at the time of clinical progression. The CA 125 response rate was 62% and 54% in the North Thames trials. In the GOG trial, it wets 66% in all 317 patients assessable for CA 125 and 67% in 221 patients whose CA 125 level was not measurable according to GOG criteria, compared with a GOG-defined response rate of 62%. The sensitivity for detecting GOG-defined response was at least 68%. Conclusion: Definitions based on a 50% or 75% decrease of CA 125 levels have been shown reliably to define partial response of ovarian cancer in patients receiving first-line chemotherapy, These definitions should be used in addition to or instead of standard response criteria. (C) 1996 by American Society of Clinical Oncology.
Keywords: ca-125; antibody; prognostic value; criteria; cancer
Journal Title: Journal of Clinical Oncology
Volume: 14
Issue: 5
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 1996-05-01
Start Page: 1545
End Page: 1551
Language: English
ACCESSION: WOS:A1996UJ40300019
DOI: 10.1200/jco.1996.14.5.1545
PROVIDER: wos
PUBMED: 8622070
Notes: Article -- Source: Wos
Altmetric Score
MSK Authors
  1. William Hoskins
    133 Hoskins